Alpha Teknova Inc (TKNO)

$3.27

+0.76

(+30.28%)

Market is closed - opens 7 PM, 25 Jul 2024

Performance

  • $3.02
    $3.69
    $3.27
    downward going graph

    7.65%

    Downside

    Day's Volatility :18.05%

    Upside

    11.26%

    downward going graph
  • $1.16
    $4.27
    $3.27
    downward going graph

    64.53%

    Downside

    52 Weeks Volatility :72.83%

    Upside

    23.42%

    downward going graph

Returns

PeriodAlpha Teknova IncSector (Health Care)Index (Russel 2000)
3 Months
46.78%
5.5%
0.0%
6 Months
-21.56%
7.2%
0.0%
1 Year
-26.93%
9.3%
0.0%
3 Years
-85.63%
13.0%
-19.9%

Highlights

Market Capitalization
121.0M
Book Value
$2.04
Earnings Per Share (EPS)
-1.05
Wall Street Target Price
5.0
Profit Margin
-97.85%
Operating Margin TTM
-71.97%
Return On Assets TTM
-14.15%
Return On Equity TTM
-41.1%
Revenue TTM
36.9M
Revenue Per Share TTM
1.05
Quarterly Revenue Growth YOY
1.9%
Gross Profit TTM
17.5M
EBITDA
-23.5M
Diluted Eps TTM
-1.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.66
EPS Estimate Next Year
-0.57
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.19

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Alpha Teknova Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
3
3
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 52.91%

Current $3.27
Target $5.00

Company Financials

FY19Y/Y Change
Revenue
20.1M
-
Net Income
-1.3M
-
Net Profit Margin
-6.49%
-
FY20Y/Y Change
Revenue
31.3M
↑ 55.75%
Net Income
3.6M
↓ 373.56%
Net Profit Margin
11.41%
↑ 17.9%
FY21Y/Y Change
Revenue
36.9M
↑ 17.88%
Net Income
-9.8M
↓ 374.59%
Net Profit Margin
-26.57%
↓ 37.98%
FY22Y/Y Change
Revenue
41.4M
↑ 12.27%
Net Income
-47.5M
↑ 384.22%
Net Profit Margin
-114.6%
↓ 88.03%
FY23Y/Y Change
Revenue
36.7M
↓ 11.43%
Net Income
-36.8M
↓ 22.52%
Net Profit Margin
-100.26%
↑ 14.34%
Q4 FY22Q/Q Change
Revenue
7.9M
↓ 26.2%
Net Income
-13.3M
↓ 40.85%
Net Profit Margin
-168.47%
↑ 41.72%
Q1 FY23Q/Q Change
Revenue
9.1M
↑ 15.59%
Net Income
-8.8M
↓ 33.68%
Net Profit Margin
-96.67%
↑ 71.8%
Q2 FY23Q/Q Change
Revenue
11.5M
↑ 26.38%
Net Income
-7.2M
↓ 18.86%
Net Profit Margin
-62.06%
↑ 34.61%
Q3 FY23Q/Q Change
Revenue
8.2M
↓ 29.13%
Net Income
-10.2M
↑ 41.92%
Net Profit Margin
-124.29%
↓ 62.23%
Q4 FY23Q/Q Change
Revenue
7.9M
↓ 3.7%
Net Income
-10.7M
↑ 4.95%
Net Profit Margin
-135.45%
↓ 11.16%
Q1 FY24Q/Q Change
Revenue
9.3M
↑ 18.09%
Net Income
-8.1M
↓ 24.01%
Net Profit Margin
-87.16%
↑ 48.29%
FY19Y/Y Change
Total Assets
58.5M
-
Total Liabilities
45.6M
-
FY20Y/Y Change
Total Assets
62.9M
↑ 7.52%
Total Liabilities
46.1M
↑ 1.19%
FY21Y/Y Change
Total Assets
166.5M
↑ 164.68%
Total Liabilities
23.3M
↓ 49.49%
FY22Y/Y Change
Total Assets
152.3M
↓ 8.56%
Total Liabilities
52.4M
↑ 124.71%
FY23Y/Y Change
Total Assets
128.6M
↓ 15.55%
Total Liabilities
38.6M
↓ 26.4%
Q4 FY22Q/Q Change
Total Assets
152.3M
↓ 5.0%
Total Liabilities
52.4M
↑ 8.49%
Q1 FY23Q/Q Change
Total Assets
141.0M
↓ 7.38%
Total Liabilities
48.9M
↓ 6.57%
Q2 FY23Q/Q Change
Total Assets
132.5M
↓ 6.01%
Total Liabilities
46.3M
↓ 5.3%
Q3 FY23Q/Q Change
Total Assets
138.4M
↑ 4.4%
Total Liabilities
38.7M
↓ 16.42%
Q4 FY23Q/Q Change
Total Assets
128.6M
↓ 7.08%
Total Liabilities
38.6M
↓ 0.47%
Q1 FY24Q/Q Change
Total Assets
120.8M
↓ 6.04%
Total Liabilities
37.4M
↓ 2.88%
FY19Y/Y Change
Operating Cash Flow
2.2M
-
Investing Cash Flow
-8.4M
-
Financing Cash Flow
8.6M
-
FY20Y/Y Change
Operating Cash Flow
2.5M
↑ 15.33%
Investing Cash Flow
-1.7M
↓ 79.24%
Financing Cash Flow
-1.6M
↓ 118.66%
FY21Y/Y Change
Operating Cash Flow
-9.1M
↓ 462.04%
Investing Cash Flow
-17.5M
↑ 909.86%
Financing Cash Flow
110.8M
↓ 7028.89%
FY22Y/Y Change
Operating Cash Flow
-27.4M
↑ 202.13%
Investing Cash Flow
-28.1M
↑ 60.66%
Financing Cash Flow
10.3M
↓ 90.73%
Q4 FY22Q/Q Change
Operating Cash Flow
-8.0M
↓ 3.64%
Investing Cash Flow
-4.7M
↓ 28.14%
Financing Cash Flow
5.1M
↑ 14585.71%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.7M
↓ 4.3%
Investing Cash Flow
-4.3M
↓ 8.84%
Financing Cash Flow
-25.0K
↓ 100.49%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.9M
↓ 49.82%
Investing Cash Flow
-2.3M
↓ 45.78%
Financing Cash Flow
-180.0K
↑ 620.0%

Technicals Summary

Sell

Neutral

Buy

Alpha Teknova Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alpha Teknova Inc
Alpha Teknova Inc
73.1%
-21.56%
-26.93%
-85.63%
-89.44%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.85%
3.8%
45.41%
51.86%
68.72%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
2.31%
10.22%
1.49%
19.3%
19.3%
Zoetis Inc.
Zoetis Inc.
4.39%
-3.6%
-3.34%
-10.68%
55.39%
Viatris Inc.
Viatris Inc.
9.84%
-1.88%
8.29%
-16.91%
-29.62%
Catalent, Inc.
Catalent, Inc.
3.45%
17.64%
21.86%
-48.3%
5.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alpha Teknova Inc
Alpha Teknova Inc
NA
NA
NA
-0.66
-0.41
-0.14
NA
2.04
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.48
39.48
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.73
29.73
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.83
34.83
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alpha Teknova Inc
Alpha Teknova Inc
Buy
$121.0M
-89.44%
NA
-97.85%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.6B
68.72%
39.48
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
19.3%
29.73
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.5B
55.39%
34.83
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.8B
-29.62%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
5.41%
211.02
-28.44%

Insights on Alpha Teknova Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 7.86M → 9.29M (in $), with an average increase of 15.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -10.65M → -8.09M (in $), with an average increase of 31.6% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 45.4% return, outperforming this stock by 72.3%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 47.6% return, outperforming this stock by 133.6%

Institutional Holdings

  • Millennium Management LLC

    4.49%
  • Balyasny Asset Management LLC

    2.56%
  • Junked Platinum Investment Management Ltd

    1.78%
  • Vanguard Group Inc

    0.97%
  • Parkman Healthcare Partners LLC

    0.73%
  • Osterweis Capital Management Inc

    0.66%

Company Information

teknova makes prepared media for bacteria and yeast applications. we have a full portfolio that includes plated and liquid growth media, as well as dry microbiological media that is available both bottled and in our propietary soluble pouch. we also have a full range of buffers, reagents and solutions, and everything we carry is available in custom formulations in order to optimize our products specifically to each of our customer's application. we have done it all before, and we challenge our customers to come up with a formulation that is a first time request.

Organization
Alpha Teknova Inc
Employees
210
CEO
Mr. Stephen Gunstream
Industry
Healthcare

FAQs